SCHEMBL6599381

SCHEMBL6599381

CC(=O)CNc1[c]cccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.34
ALDH1A1 P00352 4/20 0.33
ADORA3 P0DMS8 2/20 0.33
MAPT P10636 2/20 0.32
HSD17B10 Q99714 2/20 0.31
NAPRT Q6XQN6 1/20 0.31
PKM P14618 1/20 0.31
PTGS2 P35354 1/20 0.30
LMNA P02545 2/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
MTNR1A P48039 1/20 0.30
MTNR1B P49286 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C19 P33261 1/20 0.30
KMT2A Q03164 1/20 0.30
HIF1A Q16665 1/20 0.30
HTT P42858 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16294303 0.83 CDC25A (0.40) TDP1ALDH1A1MAPTPTGS2KDM4E
SCHEMBL3204629 0.81 CCNA2 (0.34) TDP1ALDH1A1MAPTLMNAMEN1
SCHEMBL5698142 0.79 AGTR1 (0.50) TDP1ALDH1A1MAPTLMNAL3MBTL1
SCHEMBL8152713 0.76 MAOA (0.33)
SCHEMBL7565859 0.75 KDM4E (0.44) TDP1ALDH1A1HSD17B10PTGS2LMNA
SCHEMBL97108 0.75 HSD17B10 (0.48) TDP1ALDH1A1MAPTHSD17B10NAPRT
SCHEMBL7795577 0.73 CA12 (0.42) ALDH1A1MAPTHSD17B10LMNAKDM4E
SCHEMBL8118545 0.71 CA1 (0.45) ALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL3121567 0.71 FFAR1 (0.34) ALDH1A1HSD17B10KMT2AHTTSMN1; SMN2
SCHEMBL1355267 0.71 KDM4E (0.42) ALDH1A1MAPTLMNAL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6800630-B2 CYTOSTATIC ACTIVITY, INHIBITORY ACTIVITY AGAINST A SIGNAL DERIVED FROM RAS ONCOGENE PRODUCTS SHIONOGI & CO., LTD. (JP) 2004-10-05 US disclosed
EP-1251129-B1 PYRIMIDINE DERIVATIVES HAVING ANTITUMOR EFFECT SHIONOGI & CO (JP) 2004-06-09 EP disclosed
US-20030203894-A1 Pyrimidine derivatives having antitumor effect SHIONOGI & CO., LTD. (JP) 2003-10-30 US disclosed
EP-1251129-A1 PYRIMIDINE DERIVATIVES HAVING ANTITUMOR EFFECT SHIONOGI & CO., LTD. (JP) 2002-10-23 EP disclosed
US-4139537-A 3-Aryloxy-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds COOPER LABORATORIES, INC. (US) 1979-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203894-A1 Pyrimidine derivatives having antitumor effect TYMS, TYMP, RRM1 TDP1 1260/4885ALDH1A1 1562/4885ADORA3 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.